3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Big pharma is gearing up for a new wave of acquisitions targeting mid-cap biotech companies, driven by looming patent expirations on blockbuster drugs. Three under-the-radar biotechs have emerged as prime targets, but only one combines a depressed valuation with a commercial product already gaining market share.
As patent cliffs loom for major drugmakers, Big Pharma is preparing for a new buying spree targeting mid-cap biotech companies, according to a report by 24/7 Wall St. The report warns that acquirers may have to overpay to secure deals or risk losing significant revenue.
Details
The report identified three mid-cap biotech companies as potential acquisition targets, without naming them. One stands out for combining a depressed valuation with a commercial product that is already gaining traction. These companies have quietly positioned themselves as attractive targets by developing promising pipelines or approved products.
Context
Patent cliffs are the main driver of this trend. As exclusivity expires for key drugs like AbbVie's (ABBV) Imbruvica and Bristol-Myers Squibb's (BMY) Opdivo, these companies need to replace lost revenue. Acquiring smaller biotechs is faster and often cheaper than internal R&D.
What This Means for Investors
For investors, these mid-cap biotechs may offer opportunities ahead of potential acquisition announcements, which typically boost stock prices. However, the risk is that deals may not materialize, leading to stock declines. Companies with commercial products and low valuations are the most attractive targets.
Frequently Asked Questions
Found this useful? Share it